Last reviewed · How we verify
PEG-rhGH Injection + Semaglutide Injection
This combination therapy stimulates growth hormone secretion via PEG-rhGH while simultaneously activating GLP-1 receptors through semaglutide to promote metabolic effects and weight management.
This combination therapy stimulates growth hormone secretion via PEG-rhGH while simultaneously activating GLP-1 receptors through semaglutide to promote metabolic effects and weight management. Used for Growth hormone deficiency with concurrent metabolic dysfunction or obesity, Diabetes management in growth hormone-deficient patients.
At a glance
| Generic name | PEG-rhGH Injection + Semaglutide Injection |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Growth hormone analog + GLP-1 receptor agonist combination |
| Target | Growth hormone receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology; Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
PEG-rhGH (pegylated recombinant human growth hormone) provides sustained growth hormone activity to enhance protein synthesis, lipolysis, and metabolic rate. Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, reduces glucagon, slows gastric emptying, and promotes satiety. Together, these agents target multiple metabolic pathways to address growth hormone deficiency while improving glycemic control and body composition.
Approved indications
- Growth hormone deficiency with concurrent metabolic dysfunction or obesity
- Diabetes management in growth hormone-deficient patients
Common side effects
- Injection site reactions
- Nausea
- Headache
- Arthralgia
- Fluid retention
- Gastrointestinal disturbances
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: